Table 2.
Distribution of genomic tumor characteristics by immunohistochemical-defined estrogen receptor category in Carolina Breast Cancer Study phases I, II, and III
| Characteristic | ER expression |
||
|---|---|---|---|
| <1% (n = 422; 28%) | ≥1 to <10% (n = 96; 6%) | ≥10% (n = 990; 66%) | |
| ROR-PT* | |||
| Mean score (SD) | 60.24 (20.72) | 48.61 (21.61) | 32.31 (22.30) |
| Low, No. (%) | 19 (4.6) | 8 (8.5) | 277 (28.3) |
| Medium, No. (%) | 217 (52.0) | 62 (66.0) | 622 (63.5) |
| High, No. (%) | 181 (43.4) | 24 (25.5) | 81 (8.3) |
| RFD, high vs low or medium (95% CI), %† | 67.9 (61.9 to 73.8) | 52.4 (36.8 to 68.0) | Referent |
| P‡ | <.001 | <.001 | |
| p53 status | |||
| WT, No. (%) | 155 (36.7) | 49 (51.0) | 722 (72.9) |
| Mutant-like, No. (%) | 267 (63.3) | 47 (49.0) | 268 (27.1) |
| RFD, mutant-like vs WT (95% CI), %† | 29.8 (24.7 to 34.8) | 8.0 (3.8 to 12.2) | Referent |
| P‡ | <.001 | <.001 | |
| ESR1 expression | |||
| ESR1-low, No. (%)§ | 372 (88.2) | 68 (70.8) | 158 (15.9) |
| ESR1-high, No. (%)§ | 50 (11.9) | 28 (29.2) | 836 (84.1) |
| RFD, low vs high (95% CI), %† | 63.2 (58.8 to 67.6) | 26.3 (20.2 to 32.5) | Referent |
| P‡ | <.001 | <.001 | |
*
Fifty case patients had missing PAM50 subtype, 17 case patients had missing ROR-PT. CI = confidence interval; ER = estrogen receptor; RFD = relative frequency difference; ROR-PT = risk of recurrence, proliferation and tumor size weighted; WT = wild type.
†
Adjusted for age and race.
‡
Two-sided χ2 test.
§
ER-negative defined as ESR1 messenger RNA (mRNA) less than 8.77, ER-positive defined as ESR1 mRNA greater than or equal to 8.77.